Medicine and Dentistry
Antiphospholipid Syndrome
100%
Antiphospholipid Antibody
47%
Rheumatic Disease
45%
Systemic Lupus Erythematosus
40%
Obstetrics
26%
Prevalence
23%
Heparin
20%
Acetylsalicylic Acid
20%
Disease
18%
Hydroxychloroquine
16%
Musculoskeletal Disease
16%
Connective Tissue Disease
15%
Pre-Eclampsia
14%
Vitamin K Antagonist
13%
Pregnancy Complication
13%
Chronic Kidney Disease
11%
Disease Course
11%
Rheumatology
11%
Spontaneous Abortion
10%
Infection
10%
Inflammatory Arthritis
10%
Systematic Review
9%
Lupus Erythematosus
9%
Anticoagulation
9%
Placebo
9%
Rheumatoid Arthritis
9%
Disease Activity
9%
Low Drug Dose
9%
Stillbirth
9%
Severe Acute Respiratory Syndrome Coronavirus 2
9%
Cardiovascular Risk
8%
COVID-19
8%
Prospective Study
8%
Cohort Analysis
8%
Immunogenicity
8%
Pregnancy
8%
Household
7%
Phlebothrombosis
7%
Social Determinants of Health
7%
Health Inequality
7%
Brain Ischemia
7%
Livedo reticularis
7%
Livedo
7%
Humoral Immunity
7%
Risk Stratification
7%
Acute Heart Infarction
7%
Prospective Cohort Study
7%
Direct Oral Anticoagulant
7%
Apoplexy
7%
Ankle Brachial Index
7%
Pharmacology, Toxicology and Pharmaceutical Science
Rheumatic Disease
45%
Antiphospholipid Syndrome
41%
Antiphospholipid Antibody
28%
Acetylsalicylic Acid
19%
Heparin
18%
Hydroxychloroquine
18%
Disease
17%
Clinical Trial
16%
Multiple Sclerosis
15%
Antivitamin K
13%
Infection
12%
Inflammatory Arthritis
10%
Autoimmune Disease
10%
Rheumatoid Arthritis
9%
Prevalence
9%
Cohort Study
9%
SARS Coronavirus
9%
Prospective Cohort Study
8%
COVID-19 Vaccine
8%
Vaccine
8%
Musculoskeletal Disease
8%
Prospective Study
8%
Antirheumatic Agent
8%
Immunogenicity
8%
Acute Heart Infarction
7%
Direct Oral Anticoagulant
7%
Brain Ischemia
7%
Placebo
7%
Alemtuzumab
7%
Chronic Kidney Failure
7%
Anticoagulant Agent
7%
Dexamethasone
7%
Erythropoietin
7%
Cerebrovascular Accident
7%
Vasculitis
7%
Connective Tissue Disease
7%
Immunosuppressive Agent
7%
Adverse Event
6%
Pandemic
6%
Thrombosis
5%
Low Molecular Weight Heparin
5%
Immunology and Microbiology
Antiphospholipid Syndrome
62%
Phospholipid Antibody
41%
Rheumatic Disease
30%
Systemic Lupus Erythematosus
24%
Hydroxychloroquine
16%
Prevalence
15%
Immunology
13%
Thrombin
9%
Low Drug Dose
8%
Alemtuzumab
7%
Humoral Immunity
7%
Antibody Specificity
7%
Severe Acute Respiratory Syndrome Coronavirus 2
7%
Immunogenicity
7%
Undifferentiated Connective Tissue Disease
7%
Thrombocyte Activation
7%
Multiple Sclerosis
7%
Offspring
7%
Glycoprotein
6%
Autoimmune Disease
5%
